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Integration of genetic testing into routine oncology care could improve access to testing.
This systematic review investigated interventions and the tailored implementation strategies
aimed at increasing access to genetic counselling and testing and identifying hereditary can-
cer in oncology.
Methods
The search strategy results were reported using the PRISMA statement and four electronic
databases were searched. Eligible studies included routine genetic testing for breast and
ovarian cancer or uptake after universal tumour screening for colorectal or endometrial can-
cer. The titles and abstracts were reviewed and the full text articles screened for eligibility.
Data extraction was preformed using a designed template and study appraisal was
assessed using an adapted Newcastle Ottawa Scale. Extracted data were mapped to Proc-
tor’s et al outcomes and the Consolidated Framework for Implementation Research and
qualitatively synthesised.
Results
Twenty-seven studies, published up to May 2020, met the inclusion criteria. Twenty-five
studies ranged from poor (72%), fair to good (28%) quality. Most interventions identified
were complex (multiple components) such as; patient or health professional education,
interdisciplinary practice and a documentation or system change. Forty-eight percent of
studies with complex interventions demonstrated on average a 35% increase in access to
genetic counselling and a 15% increase in testing completion.
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Mapping of study outcomes showed that 70% and 32% of the studies aligned with either
the service and client or the implementation level outcome and 96% to the process or inner
setting domains of the Consolidated Framework for Implementation Research.
Conclusion
Existing evidence suggests that complex interventions have a potentially positive effect
towards genetic counselling and testing completion rates in oncology services. Studies of
sound methodological quality that explore a greater breadth of pre and post implementation
outcomes and informed by theory are needed. Such research could inform future service
delivery models for the integration of genetics into oncology services.
Introduction
A challenge of optimising standards in oncology is the slow rate that evidence is adopted into
clinical care, leading to inequity and variation between hospital settings [1, 2]. Health services
research identifies ways to ease the burden on cancer care provision, improve system ineffi-
ciencies and optimise standards [1, 2]. In the case of cancer germline genetic testing (GT), a
systematic way to sustain implementation of GT is needed as this is increasingly being used in
the assessment and care of patients in many specialities [3]. Evidence based clinical practice
guidelines in the United States of America (USA), Australia and the United Kingdom (UK)
recommend access for epithelial ovarian cancer (EOC) and triple negative breast cancer
(TNBC) patients to have BRCA testing [4–6]. Established clinical guidelines for directing
access to GT for endometrial and colorectal cancers (EC/CRC) exist in the USA, UK and Aus-
tralia [7–9].
Direct access to GT in oncology care (known as ‘mainstreaming’) could improve access to
GT and the identification of patients with hereditary cancer. Prior to mainstreaming, access to
genetic counselling (GC) services has been through referral to genetics services. In many juris-
dictions, medical specialists in oncology can now order a panel of multiple genes to assess for
hereditary breast and ovarian cancer (HBOC) [10] without prior referral to genetic services.
Mainstreaming assumes that oncology health professionals will take on the role of pre-test GC
for GT.
Barriers to mainstreaming exist among non-genetics health professionals from a range of
specialities and include, a lack of genetics knowledge and skill, resources and guidelines, low
confidence with genetics, and concerns about discrimination and psychological harm [11, 12].
These barriers have led to suboptimal referral and identification of hereditary cancer [13, 14]
and reduce the potential for GT to inform cancer prevention through regular screening or pre-
ventative surgery [15–17]. Integrating GT into oncology services aims to circumvent recog-
nised barriers to improve the identification of BRCA related HBOC and personalise
treatments with the use of poly ADP ribose polymerase (PARP) inhibitors (PARPi) [18]. The
initial BRCA mainstreaming programs allows implementation insights to inform approaches
to improve access to GT and identification for other hereditary cancer.
Hereditary colorectal and endometrial cancer associated with Lynch Syndrome (LS) is a
parallel example where direct access to GT instead of referral to genetics services allows sur-
geons and oncologists to directly order GT. Recent changes in Australian public funding of
GT [19] in 2020, now allow medical specialists caring for EC and CRC patients to request GT
directly, as a new form of mainstreaming. Before ordering GT for CRC or EC patients,
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oncologists or surgeons need to identify deficient mismatch repair (dMMR) positive status on
a universal tumour screen (UTS) [20]. The aim of UTS is to increase the number of LS individ-
uals identified, enabling cancer screening and risk prevention and reducing the burden of dis-
ease in individuals and their families [20].
In Australia, as direct access to GT to align with UTS begins, learning from other jurisdic-
tions where GT has been part of routine oncology care, can provide important lessons. The
application of implementation science using Proctor’s evaluative framework [21] and the Con-
solidated Framework for Implementation Research (CFIR) [22] provides a means of assessing
existing interventions used to incorporate GT into routine oncology, to understand the effec-
tiveness of mainstreaming strategies and to inform its long-term sustainability.
Understanding implementation outcomes can enhance the implementation success of an
intervention. However, many studies miss out this important step, focusing the evaluation of
the interventions’ implementation on the service and client level [21]. Therefore, an imple-
mentation outcome evaluative framework provides a means to assess and evaluate implemen-
tation efforts, differentiating three groups of outcomes–implementation, service and client
[21]. The CFIR framework [22] allows an understanding of the factors that can affect imple-
mentation processes and outcomes.
Interventions are most effective when there is an understanding of the constituent compo-
nents, implementation factors in the relevant health system and the implementation outcomes
of the intervention [21, 23]. For the purposes of this review an intervention is defined as a sin-
gle unit that can bring about change in a system [23] and complex interventions are described
as ‘interventions that contain several interacting components’ [24]. The term complex refers to
the multi component nature of the health system intervention and relates to the intervention,
setting, patients and professionals interacting with it [24]. An example of a single unit inter-
vention would be education about incorporating GT into routine oncology practice. A com-
plex intervention example would consist of multiple components, for example, education/
training of staff, changes to referral pathways and use of electronic medical record to stream-
line appointments. These components, which can be described as ‘implementation strategies’,
strive to increase access to GC and GT in routine oncology practice. The specific review ques-
tion we asked was: What interventions have been shown to increase the uptake of GC and GT
in oncology services, specifically for ovarian, breast, colorectal and endometrial cancer, to
identify hereditary cancer? Interventions of interest were those that aimed to:
1. increase GT integration in oncology care (mainstreaming) for subsets of ovarian and breast
cancer in the oncology setting, and
2. increase the uptake of GT after UTS for colorectal and endometrial cancer.
Our outcomes of interest for intervention studies were:
1. Referral rates of eligible patients with breast, ovarian, endometrial and colorectal cancer
to GC
2. Breast, ovarian, colorectal and endometrial cancer patients completing GC and GT
3. Identification of hereditary cancer.
The second objective was to understand the implementation factors that influence GT
adoption in oncology services.
Our outcomes of interest for implementation factors were;
4. Qualitative or quantitative implementation outcome factors.
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Methods
This systematic review used the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses statement (PRISMA) [25] to report the search results. The protocol of the review was
not registered as it is part of a PhD program of study.
Inclusion/exclusion criteria
Study inclusion criteria were as follows;
1. A population consisting of;
• Breast, ovarian, colorectal and endometrial cancer patients > 18 years old with 80% of the
population being studied for access to GT for HBOC or uptake of GT after UTS for CRC
or EC
2. An intervention focussed on the following;
• integration of routine genetic testing through mainstreaming for breast and ovarian cancer
in oncology services
• increasing GC and GT completion rates after UTS for CRC and EC
3. A comparator consisting of the following;
• Another intervention with the same purpose described in intervention section above
• No intervention (in the case of qualitative studies)
• Standard or usual care
4. Outcomes focusing on Proctor’s evaluative framework and CFIR’s five implementation fac-
tor domains as follows;
• Implementation outcomes and factors
• Service outcomes and factors
• Client outcomes and factors
5. Study designs as specified below;
• Experimental, quasi-experimental and observational study designs (randomised control
trials, cohort studies, controlled pre and post studies, case series).
• Qualitative studies on implementation factors or outcomes that influence genetic testing
adoption in oncology
6. Organisation setting;
• Any healthcare system engaging in integrating GT into oncology services.
A study was excluded if it focused on patients with other cancers not related to HBOC and
LS or asymptomatic individuals or relatives at high risk of these conditions. Additionally, a
study was excluded if the outcomes were not linked to mainstreaming of GT or enhancing the
uptake of UTS.
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Search strategy
A search strategy was developed by checking the subject headings and text terms used for the
area of interest. An initial draft was reviewed with systematic review experts (CC SH) and
trialled on MEDLINE. The search terms were revised by ROS and systematic reviewers (CC)
and the final version included search terms for ovarian, breast, colorectal and endometrial can-
cer, combined with genetic counselling, genetic testing, mainstreaming, and implementation
science terms (S1 Table). This strategy was then translated for use in CINAHL (S2 Table). The
strategy was executed in four databases on 26.09.19: MEDLINE, EMBASE, PsychINFO and
CINAHL and alerts from this search were screened until 26.05.20 A list of included studies is
in the Supporting information.
Study selection
All of the titles and abstracts were exported to Endnote X8 and screened by ROS indepen-
dently against the inclusion criteria. Full text articles of those with unclear or missing informa-
tion were retrieved and screened by ROS against the inclusion criteria. Studies meeting the
inclusion criteria were retained. ROS obtained all relevant full texts articles and randomly
assigned these to two other reviews through Excel. Full text articles were screened for eligibility
by three reviewers (ROS, AC and CC) and the reasons for excluding articles were documented
in Excel. Any disagreements were resolved through initial discussion between the three
reviewers and if no consensus was reached, a fourth reviewer was considered an arbitrator.
Data extraction
Data was extracted from each included study on population (healthcare professional, setting
and patient); description of the intervention (adapted criteria template for intervention
description and replication (TIDieR) checklist [26]); implementation study dates, use of a
model or framework, study design and intervention outcomes for the implementation period
were assessed by mapping to all of the components of Proctor et al.’s evaluative framework
[21] at the implementation, service or client level and all CFIR [22] domain and relevant con-
structs; and information for quality appraisal (S4 Table). Two reviewers (ROS, CC) extracted
data from two included studies and compared results. Discrepancies were discussed and a con-
sensus reached for future data extraction. One reviewer (ROS) independently completed data
extraction for the remainder of the included studies (S4 Table).
Quality appraisal
The quality assessment of each included study was assessed using an adapted Newcastle
Ottawa Scale (NOS) [27] for cohort studies and further adapted for case series with implemen-
tation outcomes. The adapted NOS evaluated selection bias, study design, confounders, blind-
ing of study participants, data collection methods, and follow up rates. The tool was
independently applied by two reviewers (AC, ROS) and consensus was reached on any dis-
crepancies through discussion. The star rating for each component was then converted to
Agency for Healthcare Research and Quality (AHRQ) rating from poor to good quality. Quali-
tative studies were assessed using the Critical Appraisal Skills Programme (CASP) [28].
Data synthesis
Descriptive data analysis was preformed to summarise study characteristics through propor-
tions or percentages on study design and location, types of health professionals and patients
targeted with the intervention, the hospital setting used and quality appraisal. Heterogeneity in
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intervention characteristics, measured outcomes, and small sample sizes did not allow for a
meta-analysis. A narrative synthesis was performed to summarise and explain the intervention
characteristics and potential effects. The intervention effectiveness (absolute difference) was
measured for studies with intervention and control data (S4 Table). Due to the heterogeneity
of intervention components, a domain directed intervention classification system was created
(Table 1). We used the designed intervention classification system (Table 1), Proctor’s evalua-
tive framework [21] and CFIR [22] as the sensitising lens for thematic analysis. Each study’s
outcomes were mapped to Proctor’s implementation, service and client outcomes and imple-
mentation factors through CFIR’s domains and constructs. The development of themes and
subthemes was informed from this overarching structure. Each study was checked and
referred to as per the disease context (breast and ovarian cancer versus colorectal and endome-
trial cancer) as themes were incorporated into a narrative synthesis. Three reviewers (AC, NR,




Studies and location. Of the 2224 titles generated through database-searching (Fig 1), we
included 27 [29–55] studies of which 25 [29–48, 51–55] described interventions. The majority
Table 1. Classification of intervention components into four distinct domains.
Complex intervention [24] type Implementation strategies [23]
Education (health professional or patient) Face to face education
Online education
Written information
Family history collection proforma
Interdisciplinary practice Genetic counsellor at multidisciplinary team
(MDT) meeting
Embedded Genetic counsellor in oncology
Genetic counsellor or oncologist facilitates
communication
Genetics or oncologist led referral pathway
Patient navigators
Documentation (GC referral, GT outcomes and written
information to facilitate mainstreaming)




Standardised letters for results
Consent form
Systems (electronic or process) Smart text for EMR or pathology reporting
Synchronous scheduling of GC
appointments
Shared GC referral or review e-mail inbox
E-mail alerts
E-mail notifications for referral
EMR GC referral
Result tracking
MDT multidisciplinary team, EMR electronic medical record, GC Genetic Counselling, GT Genetic testing.
https://doi.org/10.1371/journal.pone.0250379.t001
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of included studies (44%) were from North America [34–39, 41, 44–47, 54] (Table 2). The 25
studies [29–48, 51–55] (93%) described interventions to increase access to GC and GT through
mainstreaming or UTS initiatives (S4 Table). The study designs found were retrospective or
prospective cohort studies with concurrent or historical controls (44%) [34, 36, 37, 42–47, 54,
55] or case series that reported on intervention outcomes (56%) [29–33, 35, 38–41, 48, 51–53]
(Table 2). Two qualitative studies [49, 50] and eight of the intervention studies (with a qualita-
tive or quantitative component) [29–31, 33, 40, 48, 51, 54] described implementation out-
comes that relate to acceptability and cost of interventions (Table 5, S4 Table).
Participants. Twenty-one studies included a variety of healthcare professionals (years of
practice not indicated) exposed to the interventions (Table 2) and four studies did not specify
the health professionals involved. The numbers of patients exposed to the intervention in the
Fig 1. Flow chart summarizing identification of studies for inclusion in this systematic review using PRISMA [25].
https://doi.org/10.1371/journal.pone.0250379.g001
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studies ranged from 16 to 1214. Nearly half of the studies (44%) [30, 32, 33, 36, 37, 41, 43, 46,
47, 51, 54] had fewer than 200 patients exposed to the intervention. Seventeen studies (68%)
reported participants’ ages [29, 31–33, 35–37, 39–41, 45, 46, 51–55] and 14 (56%) reported
subtypes of cancer [29, 31–33, 35, 37–40, 43, 45, 46, 51, 52].
Interventions, setting and framework. The majority of studies used complex interven-
tions (Table 1, S4 Table) to increase access to GC and GT, either in the routine oncology set-
ting [29–40, 51–55] or optimizing referral to genetic services for GC and GT [45–47] for
ovarian or breast cancers and through optimizing access to genetic services after UTS in colo-
rectal and endometrial cancer [39, 41–44]. The 25 studies spanned a variety of health systems
(Table 2) with six studies (24%) included either a quality improvement or process model [35–
37, 39, 40] or an implementation science framework [42] to guide implementation. None of
the studies used an evaluation framework to underpin the outcomes with a robust assessment
of intervention effectiveness.
Quality assessment. Fifty-six percent of the studies (n = 14) received a poor AHRQ rating
due to the study design–case series with no comparator [29–33, 35, 38–41, 48, 51–53], selection
bias in the use of a single site health system [29, 30, 39, 40, 47, 48] and/or no statistical
Table 2. Summary of included studies and participants’ characteristic.
Health professionals targeted Breast and ovarian cancer intervention (n = 20) Colorectal and endometrial cancer
intervention (n = 5)
Number of studies/Total
(%)
References Number of studies/Total
(%)
References
Genetic counsellors 12/20 (60%) [29, 31, 33, 35, 37, 38, 41, 43, 46, 48, 53,
54]
3/5 (60%) [42, 44, 47]
Medical oncologists 13/20 (65%) [29, 30–33, 37, 43, 45, 48, 51, 53–55] 2/5 (40%) [42, 47]
Gynaecology oncologists 9/20 (45%) [29, 33, 35, 38, 39, 45, 46, 53, 55] NA
Clinical nurse specialists 5/20 (25%) [29, 30, 33, 37, 55] 3/5 (60%) [39, 41, 42]
Advanced nurse practitioners 3/20 (15%) [35, 38, 39] NA
Clinical geneticists 4/20 (20%) [37, 43, 48] 2/5 (40%) [42, 47]
Resident or fellow or trainee 2/20 (10%) [35, 37]
Other 1/20 (5%) [38, 45]
Pathologists NA 5/5 (100%) [39, 41, 42, 44,
47]
Surgeons NA 4/5 (80%) [41, 42, 44, 47]
Location all studies n = 27
North American and Canada 12/27 (44%) [34–39, 41, 44–47, 54]
United Kingdom 8/27 (30%) [29, 30, 31, 32, 40, 50, 51, 52]
Australia 5/27 (18%) [33, 48, 43, 42, 49]
Europe 2/27 (7%) [53, 55]
System setting n = 25
Single site urban hospitals 16/25 (59%) [29, 30, 33, 36, 37, 39, 40, 43, 46, 47, 51, 52, 55]
Large multi-site urban and regional
hospital
6/25 (24%) [34, 35, 38, 41, 44, 53]
State wide systems 3/25 (12%) [43, 45, 54]
Unspecified health system 1/25 (4%) [42]
Study Design n = 27
Cohort 11/27 (40%) [34, 36, 37, 42–44, 46, 47, 54, 55]
Case series 14/27 (51%) [29–33, 35, 38, 39–41, 48, 51–53]
Qualitative 2/27 (7%) [49, 50]
https://doi.org/10.1371/journal.pone.0250379.t002
PLOS ONE Interventions to integrate genetic testing into routine oncology services
PLOS ONE | https://doi.org/10.1371/journal.pone.0250379 May 19, 2021 8 / 36
adjustment for patient population differences or assessment of confounders [30, 42, 47] (S5
and S6 Tables).
Thirty-six percent of the studies received a fair to good AHRQ rating (n = 9) and were
cohort studies with a historical or concurrent comparator [34, 36, 37, 44–47, 54, 55]. Statistical
analysis was preformed between intervention and control but were not adjusted for differences
in patient population characteristics or confounders, apart from two studies [46, 54] that per-
formed regression analysis (S4 Table). All studies except two [44, 45] had>80% of the patient
population followed up in the study period.
Ninety-one percent (10/11) of historical or concurrent cohort studies had between 10
months to three and a half years when the intervention was implemented [34, 36, 41–46, 54,
55], allowing sufficient follow up time for outcomes to be measured. The two qualitative stud-
ies [49, 50]. assessed using the CASP tool [28] reached a high-quality rating score with all ques-
tions (1–10) addressed in each study.
Mapping of outcomes and studies to framework. About two-thirds of studies (64%)
measured the following outcomes to assess the adoption of the intervention at the service level;
GC recommendation and referral, GC and GT completion rate and at the client level, through
identification of hereditary cancer (68%) and treatment management impact (Table 3). About
one-third of studies measured implementation level outcomes, acceptability through satisfac-
tion with the intervention (32%) and cost effectiveness (16%). Studies focussed on the process
domain of CFIR in relation to engaging with health professionals in the implementation effort
(96%) and on executing (24%) using a process model or implementation framework to execute
the implementation plan (Table 3). The available resource construct of the inner setting
domain mapped to 96% of studies using the health professional as the resource for implemen-
tation efforts and access to knowledge and information about the intervention (64%), through
education as a core component of the intervention. Twelve percent of studies mapped to the
process domain-reflecting and evaluating through health professional’s feedback about the
intervention. Characteristics of individuals—self-efficacy (16%) and outer setting—patients’
needs and resources (n = 6) or intervention characteristics–cost (16%) were also addressed
(Table 3).
Intervention outcomes and implementation factors
The following themes describe the potential effects of complex interventions for the integra-
tion of GT in ovarian, breast, colorectal and endometrial cancer settings along with outcomes
and factors at the implementation, service and client level.
Increasing access to genetic counselling and genetic testing in routine
oncology for ovarian and breast cancer
Twenty-five studies described interventions to increase access to GC and completion of GT in
breast and ovarian cancer patients through; referral rates to GC [29, 34–39, 46–48, 52, 53, 55],
GC [34–40, 46–48, 51–54] or GT completion [31, 34–40, 47–48, 51–55], identification of
hereditary cancer [29, 43, 31–36, 40, 48, 51, 52, 54, 55], time to gain access to GT and results
[29, 31–33, 35, 45, 52, 54], treatment management impact [29, 33, 52, 55] and uptake of predic-
tive testing in families [29, 32, 45] (S4 Table). The implementation strategies used were varied
and classified under complex intervention type of education, documentation, interdisciplinary
practice or electronic systems domains (Table 1). Twenty studies mapped to Proctor’s evalua-
tive framework [21] at the service or client level measuring effectiveness through the outcomes
outlined above [29–40], [43–46, 51–55] (Table 3). CFIR [22] mapped to implementation pro-
cess factors through the executing and engaging constructs with five studies using a quality
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Table 3. Proctor et al.’s implementation outcome framework [21] and CFIR [22] applied to outcomes of included studies.
Domain Description Measure No. of intervention
studies/Total (%)
Implementation outcomes and factors
Proctor et al. [21]. (hereafter ‘Proctor’)
Implementation outcomes
• the effects of deliberate and purposive
actions to implement new treatments,
practices, and services [21]
Acceptability
The perception among implementation stakeholders that
a given treatment, service, practice, or innovation is
agreeable, palatable, or satisfactory [21]
• Patients or healthcare professionals’
satisfaction with the mainstreaming
intervention [29–31, 33, 40, 48, 51, 54]
8/25 (32%)
Cost
The cost impact of an implementation effort [21] • implementation cost of intervention or





Quantitative and qualitative feedback about the progress
and quality of implementation accompanied with regular
personal and team debriefing about progress and
experience [22]
• Healthcare professionals’ feedback about
the intervention [40, 42, 54]
3/25 (12%)
Self-efficacy Characteristics of individuals
Individual belief in their own capabilities to execute
courses of action to achieve implementation goals [22]
• Healthcare professionals’ belief about




Costs of the innovation and costs associated with
implementing the innovation including investment,
supply, and opportunity costs [22]
• implementation cost of intervention or
cost savings [29, 31, 40, 48]
4/25 (16%)
Service outcomes and implementation factors
Proctor
Service Outcomes
• the extent to which services are safe,
effective, patient -centred, timely,
efficient, and equitable [56, 57]
Effectiveness
Providing services based on scientific knowledge to all
who could benefit [56, 57]
• GC Referral [29, 34–39, 41, 42, 44, 46–
48, 52, 53, 55]
• GC completed [34–41, 44, 46–48, 51–54]
• GT completed [31, 34–41, 44, 47–48, 51–
55]
• Patients with identified gene mutations




Reducing waits and sometimes harmful delays for both
those who receive and those who give care [56, 57]
• Time to GC or GT [32–35, 52] and
results [29, 31–33, 54]
10/25 (40%)
Equity
Providing care that does not vary in quality because of
personal characteristics [56, 57]
• GT access and undertaken [31, 34–41,
44, 47–48, 51–55]
• GC referrals [29, 34–39, 41, 42, 44, 46–






Carrying out or accomplishing the implementation
according to plan [22]
• use of a quality improvement or process
model [35–37, 39, 40]




Attracting and involving appropriate individuals in the
implementation and use of the intervention through a
combined strategy of social marketing, education, role
modelling, training, and other similar activities [22]
• Engaging health professionals through
education or implementing the
intervention [29, 30–48, 51, 52, 54, 55]
24/25 (96%)
Inner setting Readiness for Implementation–Available resources
The level of resources dedicated for implementation and
on-going operations, including money, training,
education, physical space, and time [22]
• use of health professional as a resource
for implementation [29–48, 51, 52, 54, 55]
24/25 (96%)
Access to Knowledge & Information
Ease of access to digestible information and knowledge
about the intervention and how to incorporate it into
work tasks [22]
• use of education as a component of the
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improvement or process model [35–37, 39, 40] carrying out implementation according to a
plan and 20 studies engaging health professionals through education or implementing the
intervention [29–40, 43, 45, 46, 48, 51, 52, 54, 55] (Table 3).
Nine studies showed a potential positive effect in favour of the intervention having an
impact mainly on GC referral [34, 36, 38, 43, 44, 46, 55] and GC and/or GT completion [34,
36, 38, 43, 45, 46, 55]. Thirteen studies revealed an unclear intervention impact in relation to
all outcomes with no comparator presented for assessment [29, 31, 32, 33, 35, 39, 40, 47, 48,
51–54].
Complex interventions—Education, documentation and electronic system. Four stud-
ies [36, 37, 45, 46] used complex interventions related to education, documentation and elec-
tronic system domains. One of these studies [36], employed a complex intervention consisting
of education (patient and clinicians), documentation (smart text and written handouts in
EMR and for patient) and electronic system (EMR documentation of GC referral and outcome
in MDT, GC appointment scheduling). The outcomes assessed showed a significant difference
in GC referral rates (+51.2 (95% CI 43.9–58.5) p�0.001), patients completing GC (+54 (95%
CI 45.3–62.8) p�0.001) and GT (+13.2 (95%CI 3.3–23.3) p = 0.007), between the intervention
and control [36]. Another study [37] used a complex intervention consisting of health profes-
sional and patient education (written information, family history collection proforma), docu-
mentation (EMR documentation of referral for GC/GT and testing protocol pathway) and
systems (scheduling GC appointments directly at gynaecology clinic) showed a trend towards
the intervention for GC referral (+27.4 (95% CI 11.1–43.7) p = 0.02) and completion of GT
(+20.6 (95% CI 5.9–35.4) and towards the control for completion of GC (-27.8 (95% CI -46.7
to -9.1)) and identifying hereditary cancer (- 17.9 (95% CI– 40.9–5.1) p = 0.17). This study was
limited by a small study sample size and short follow up period.
Two studies [45, 46] employed an education, documentation and systems complex inter-
vention. The education (clinicians educated on EOC GC referral guidelines) and systems (use
of smart text to refer all EOC to GC on the pathology report) intervention showed an absolute
difference in eligible serous histology patients completing GC and GT (+13.7% (95% CI 7.6–
19.1) [45] (Table 4).
Table 3. (Continued)
Domain Description Measure No. of intervention
studies/Total (%)
Client outcomes and implementation factors
Proctor
Client Outcomes
Consumer wellbeing and clinical
effectiveness [21]
Satisfaction
The consumers’ satisfaction with the intervention used
[21]
• Patients satisfaction with mainstreaming
intervention [29–31, 48, 51, 52]
6/25 (24%)
Symptomology
Identifying hereditary cancer so that patients and health
professionals can enact treatment management and
cancer prevention strategies
• Identification of hereditary cancer [29,
43, 31–36, 39–41, 44, 48, 51, 52, 54, 55]
• Access or referral to cancer prevention
information [29, 32, 45, 55]







Patient Needs & Resources
The extent to which patient needs, as well as barriers and
facilitators to meet those needs, are accurately known
and prioritized by the organization [22]
• Patients satisfaction with mainstreaming
intervention [29, 30, 31, 48, 51, 52]
6/25 (24%)
GC Genetic Counselling GT Genetic testing.
https://doi.org/10.1371/journal.pone.0250379.t003
PLOS ONE Interventions to integrate genetic testing into routine oncology services
PLOS ONE | https://doi.org/10.1371/journal.pone.0250379 May 19, 2021 11 / 36
Table 4. Implementation strategies in the various health system and professional settings grouped by complex intervention effects results.
Reference Population and setting Implementation strategies Absolute Difference % Framework mapping Study Quality and design




All gynaecology oncology providers
non-specified
Patients: All women with EOC
Healthcare Institution:
Academic cancer centre





GC at MDT or









Outcome 1. Rates of GC/GT
recommendation in EHR
+ 67.7% (95% CI 59.8–75.6) p value
not provided
Outcome 2. GC referral
+51.2% (95% CI 43.9–58.5, p �0.001)
Outcome 3. GC completion
+54% (95% CI 45.3–62.8, p �0.001)
GT completion
+13.2% (95% CI 3.3–23.3, p = 0.007)
Outcome 4 Patients identified with
BRCA mutations




























Cohort study with historical control
Single site health system and no
analysis on confounding variables or
regression analysis on the
characteristics inherent in the
control verses the intervention










All women with EOC
Triple Negative Breast
Cancer < 60years
Breast Cancer < 45 years
Healthcare Institution:
Comprehensive not-for-profit system
with more than 900 care locations in 2
states, including academic medical
centres, hospitals, freestanding
emergency departments, health care










advanced care providers on
guidelines
Referral to GC was made a
standard of practice
Outcome 1. GC referral
EOC
+59.7% (95% CI 50.2–69.4, p<0.05)
TNBC < 60 yrs
+21.2% (95% CI 10.6–31.8, p<0.05)
BrCa < 45 yrs
+6.3% (95% CI -1.0–13.5) p value not
provided
Outcome 2. GT completion
EOC
+29% (95% CI 16.8–41.2, p<0.05)
TNBC < 60 yrs
+26.6% (95% CI 14.9–38.4, p<0.05)
BrCa < 45 yrs
+15.7% (95% CI -7.5–6.1, p<0.05)
Outcome 3. Patients identified with
BRCA mutations
EOC
+7.5% (95% CI– 7.9–23, p = 0.53)
TNBC < 60 yrs
+0.22% (95% CI -8.2–12.6) p value not
provided
BrCa < 45 yrs

























Case series with no comparator to
control
(Continued)
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Table 4. (Continued)








All colorectal and uterine cancer
Healthcare Institution:
Medical Centre Cancer Institute’s
Cancer Risk and Prevention Clinic—
community hospital and a state
tertiary centre with a GC-supported
cancer genetic program
Triggered GC referral after
abnormal IHC and MSI
Pathology communication
via e-mail to surgeon
Patient navigator to ensure
follow through to GC for
abnormal IHC and MSI
Outcome 1. GC referral
I: 16/16 (100.0)
C:12/12 (100.0)
p value not provided
Outcome 2. GC completion
+45.8% (95% CI 13.6–78.1, p = 0.020)
Outcome 3. GT completion
+12.9% (95% CI -24.7–50.4)
p value not provided
Outcome 4. Patients identified with
BRCA mutations
+28.8% (95% CI -21.5–79.2)
































All patients with colorectal cancer
Healthcare Institution:
Academic and tertiary (2 regional
community hospitals) and primary
care centres (multiple family health
centres)
Triggered EMR GC referral
after abnormal IHC and
MSI to surgeon
EMR documentation of
GC/GT and/or referral via
email
GC embedded to increase
communication of
abnormal IHC to patients
and facilitate referral
Shared GC e-mail to review
all abnormal MSI and IHC
from pathologist to GC
Outcome 1. GC referral
GC v No GC
+44.7% (95% CI 28.1–60.5, p<0.001)
GC & Surgeon v No GC
+26.5% (95% CI -1.2–54.2, p = 0.023)
Outcome 2. GC completion
GC v No GC
+39.8% (95% CI 20.9–58.8, p<0.001)
GC & Surgeon v No GC
+32.0% (95% CI 0.017–64)
p value not provided
Outcome 3. GT completion
GC v No GC
+39.8% (95% CI 21.1–58.5, p<0.001)
GC & Surgeon v No GC
+19.2% (95% CI -13.4–51.7)
p value not provided
Outcome 4. Patients identified with LS
GC v No GC
+22.5% (95% CI 7.7–37.2)
GC & Surgeon v No GC
+1.2% (95% CI -17.8–20.2)
p value not provided
Outcome 5. Time to appointment
GC v No GC1–413 days p<0.001
GC & Surgeon v No GC -164 days





• GC apt uptake
Timeliness


















Cohort study with historical control
Single site health system with no
analysis on confounding variables or
regression analysis on the
characteristics inherent in the
control verses the intervention
population or health system




















Outcome 1. GC referral
+22.8% (95% CI 16.7–29.4,
p<0.00001)
Outcome 2. GC completion
+45.5% (95% CI 33.6–57.6,
p<0.00001)
Outcome 3. Time to gain access to GC
I: 1.67 months





















Cohort study with historical control
Group 2: Results trend towards complex or single unit intervention
(Continued)
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Table 4. (Continued)







Medical and gynaecology oncologists
Patients:
All patients with serous, endometroid
and clear cell ovarian cancer type
Healthcare Institution:
State wide Hereditary cancer program
Education to healthcare
professionals on GC and




to refer to GC included on
the pathology report
Outcome 1. GC and GT completion
by histopathology
Serous
+13.7% (95% CI 7.6–19.1)
(OR = 4.70; 95% CI 2.89–7.62)
Endometrioid
-6.3% (95% CI -6.4 to– 2.4)
Clear cell
-3.3% (95% CI -6.2 to -0.4)
Unknown
-4.2%
P< 0.001 serous vs endometroid and
clear cell cancers getting GT after 2010
Outcome 2. Patients identified with
BRCA
Serous histopathology
+6.2% (95% CI -6.1 to 19.4, P = 0.519)
Outcome 3. Cancer prevention
Familial predictive GT uptake and
mutation identification
Carrier tests
+0.73% p = 0.071
Family members identified as BRCA
+0.56% p = 0.009
Carrier tests per serous histopathology
+ 0.76% P = 0.098
Family members identified as BRCA
positive





















Fair to poor quality
Cohort study with historical control
Multisite health system but with no
analysis on confounding variables or
regression analysis on the
characteristics inherent in the
control verses the intervention
population or health system








All women with EOC
Healthcare Institution:
Primary academic metro Women’s
Cancer Centre
EMR referral to GC
EMR documentation of GC
referral
Use of referral guidelines
and checklist
Outcome 1. GC referral
+12.7% (95% CI -0.04–25.4, P = 0.053)
Outcome 2. GC completion
+9.9% (95% CI– 0.41–20.4)



















Cohort study with historical control
Single site with regression analysis
on the characteristics inherent in the
control verses the intervention
population or health system but no








All patients with EOC < 70 years old
Healthcare Institution:
Metropolitan hospital




Outcome 1. GC referral
+25% (95% CI 13.6–36.4, P < 0.0001)
Outcome 2. GC completion
-7.4% (95% CI– 16.8 to 1.9)
p value not provided
GT completion
-16% (95% CI -32.9 to– 0.14)
p value not provided
Outcome 3. Patients identified with
BRCA mutations
+1.9% (95% CI -22.9–26.9)


















Cohort study with historical control
State-wide health system with no
analysis on confounding variables or
regression analysis on the
characteristics inherent in the
control verses the intervention
population or health system
(Continued)
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Table 4. (Continued)












Single site urban hospital, Madrid
Spain
Oncologist led pathway and
communication
MDT oncology led
Outcome 1. Eligible for GC referral
+0.97% (95% CI -3.3–5.3)
p value not provided
Outcome 2. GC referral
+25.4% (95% CI 16.4–34.3,
p < 0.0001)
Outcome 3.GT completion
-11% (95% CI -23.3–0.069)
p value not provided
Outcome 4. Patients identified with
BRCA mutations
-5% (95% CI -18–8)
p value not provided
Outcome 5. Cancer prevention
management impact























Fair Quality Cohort study with
historical control
Single site health system and no
analysis on confounding variables or
regression analysis on the
characteristics inherent in the
control verses the intervention
population or health system
Unclear how many patients followed
up








Patients: All women with EOC
Healthcare Institution:










Outcome 1. GC and GT referral
I: 207/207 100% C: NR
p value not provided
2.Time to gain access to genetic test
results
I: Four-fold reduction in time to result
C:NR
p value not provided
Outcome 3. Patients identified with
BRCA mutations
I: 33/207; 16% C: NR
p value not provided




I: 31/32 with mutations breast cancer
surveillance
C: NR





























• Access to cancer
prevention
information


















Case series with no comparator to
control
Single site health system
(Continued)
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Table 4. (Continued)








Patients: All women with EOC
Healthcare Institution:




GC embed in oncology
services
GC at MDT or




Outcome 1: GC referral
+30.4% (95% CI 20.2–40.6, p�0.001)









p value not provided







p value not provided
Outcome 4. Familial predictive GT
uptake
I:31/120 (28) C:NR







• Time to gain access





















Case series with no control










Urban Australian Familial Cancer
Centre
Genetic counsellor led




Outcome 1. GC referral
I: 284 C: NR
p value not provided
2. GC and GT completion
I: 284 C: NR
p value not provided
Outcome 3. Patients identified with
BRCA mutations
I: 26/284; 9%
12/284; 4% variants of unknown
significance (VUS)
C: NR







































Case series with no comparator to
control
Single site health system
(Continued)
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Table 4. (Continued)










All women with EOC
Healthcare Institution:
An academic cancer
centre’s (regional and main campus
clinics)
Education and direct access
to GT via gynaecology








Outcome 1–3. GC referral
I:561/1214 (46.2%) main campus
clinic
PCGT 84/151 (55.6%) regional clinic
653/1214 (53.8%) outside institution
C: NR
p value not provided
I: AGCR 33/34 (97%) signed GC
electronic referrals
14/72 (19.4%) email referrals
C: NR
p value not provided
Outcome 4. GT completion
I: 1214/1423 (85.3%) C: NR
p value not provided
Outcome 5. Patients identified with
BRCA mutations
I: 217/1214 (17.9%) C: NR
p value not provided
Outcome 6. Time to gain access to GC
Absolute difference -119 days

































Advanced practice registered nurses
Patients
Ovarian and uterine cancer patients
Healthcare Institution:






EMR tracking and referral
with e-mail notifications to
refer
Outcome 1. GC referral
I: 48/57 (84.2%) C: NR
(p = 0.02)
Outcome 2. GC and GT completion
I: 43/48 (89.6%) completed GC
39/43(90.7%) completed GT
C: NR (p = 0.03)
Outcome 3. Patients identified with
mutations
I: 8/39 (20.5%) C: NR



























Case series with no comparator to
control
Single site health system
(Continued)
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Table 4. (Continued)




Clinical nurse specialist in oncology
Medical oncologists
Patients:
All women with EOC
Healthcare Institution:
Single centre urban hospital
Online education on pre-
test GC for nurses
Written information on








Outcome 1. Patient satisfaction
No difference in patient satisfaction
between those consented by a nurse or
a doctor
No patients refused GT, or requested a



























Case series with no comparator to
control

















Outcome 1. GT completion
I: 122/NR C: NR
p value not provided
Outcome 2. Patients identified with
BRCA mutations
I: 18/122 (14.8%) C: NR
p value not provided
Outcome 3. Time to gain access to GT,
results & GC referral
I: The time from sample receipt to
result was between 14–48 working
days—GC referral between 12–43
working days after MGT results
-20/56 (36%) had MGT
within 1 month of diagnosis
C: NR
No stats
Outcome 4. Treatment management
impact
I: 11/18 (67%) no change in
management
6/18 (33%) access PARP inhibitors
C: NR
No stats
Outcome 5. Familial predictive GT
uptake
I: 11/ 15 family members of BRCA



























Case series with no comparator to
control
Single site health system
(Continued)
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Table 4. (Continued)







Patients: All women with EOC
Healthcare Institution:
Rural and urban publicly funded
hospitals of different sizes, ranging
from smaller district general hospitals
to large regional centres
Written information on
pre-test GC for patients
Genetics co-ordinated
mainstreaming pathway
Post–test GC by GC
Outcome 1. GT completion
I: 232/281 (83%) C: NR
p value not provided
Outcome 2. Patients identified with
BRCA mutations
I: 18/232 (8%) C: NR
p value not provided
Outcome 3. Time to gain access to
genetic test results
I: Consent to results
delivery 46 working days
C: NR








































Case series with no comparator to
control











Patients with colorectal cancer
Healthcare Institution:
An outpatient cancer care centre for
oncology patients treated at a tertiary
academic National Cancer Institute
(NCI)-designated Comprehensive
Cancer Consortium
Triggered GC referral after
abnormal IHC and MSI
Handouts on referral
process for LS for
healthcare professionals
Results tracking by nurse
Shared GC e-mail to review
all abnormal MSI and IHC
Electronic communication
with doctor
Scheduling GC and CRC
clinic appointments
synchronously
Outcome 1. GC referral
+9.4% (95% CI -7.9–26.8)
p value not provided
Outcome 2. Completion of GC
+9.4% (95% CI -7.9–26.8)
p value not provided
Outcome 3. GT completion
+10% (95% CI -47.6–67.6)
p value not provided
Service: Effectiveness
• GT undertaken













Cohort study with historical control
Single site health system with no
analysis on confounding variables or
regression analysis on the
characteristics inherent in the
control verses the intervention
population or health system
(Continued)
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Table 4. (Continued)





















Outcome 1: GT completion
I: 1184/1184 (100%) C: NR
p value not provided
Outcome 2. GC completion after GT
I: 115/117 (98.3%) C:NR
p value not provided
Outcome 3. Patients identified with
BRCA mutations
I: 117/1184 (9.9%) C: NR










































Case series with no comparator to
control
Single site health system
(Continued)
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Table 4. (Continued)








Breast and ovarian cancer patients
Healthcare Institution:
Population state based cancer
program in Canada








I: Patients indicated comfort and
acceptability with the GT process—no
difference between oncology clinic-
based model (OCB) and the
traditional model (TM). OCB
M = 4.54, SD = 0.71 vs TM M = 4.52,
SD = 0.69. See Table 5 below
C: NR
Outcome 2. GC completed
+58.6% (95% CI 49–68) and +8.5%
(95% CI -8.2–25) in person and
videoconference P< 0.001 OCB vs TM
Outcome 3. GT completed
+8.5% (95% CI -8.2–25 and +7.6%
(95% CI -9.4–25, p = 0.015) OCB vs
TM
Outcome 4. Patients identified with
BRCA mutations
+3.1% (95% CI -6.7–13) p = 0.507
OCB vs TM
Outcome 5. Time to gain access to GT
results





































Good to Fair quality
Cohort study with concurrent
control
State-wide health system with
analysis on confounding variables or
regression analysis on the
characteristics inherent in the
control verses the intervention
population or health system
Representation of patient population
selective–all patients didn’t complete





















Outcome 1. GC referral
I:131/356 (36.8%) C: NR
p value not provided
Outcome 2. GC completion
I:125/356 (34.6%) C: NR
p value not provided
Outcome 3. GT completion
I:125/131 (95.4%) C: NR






















Case series with no comparator to
control
(Continued)
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Table 4. (Continued)



















Outcome 1. GC referral
I:255/268 (95%) C: NR
p value not provided
Outcome 2. GC and GT completion
I:255/268 (95%) C: NR
p value not provided
Outcome 3. Patients identified with
BRCA mutations
I:34/255 (13.3%) C: NR
p value not provided
Outcome 4: Time to gain access to GT
I: Turnaround time between blood
sample and return of GT result was
20.6 (11–42) calendar days
C: Turnaround time of 148.2 calendar
days prior to I
Outcome 5. Treatment management
impact




15/34 still receiving first-line
(adjuvant) treatment or in remission
—not eligible for PARPi
5/34 ineligible to receive PARPi C: NR
p value not provided
Service:
Efficiency

























Case series with no comparator to
control


















I: Decision Regret Scale 9.14±12.397–
14/29 (48.3%), reported no decision
regret
26/29 (89.6%) were satisfied with their
decision to pursue GT
Participants produced relatively low
MICRA scores regardless of mutation
status
C: NR p value not provided
Outcome 2. GC completion
I:170/170 (100%) C: NR
p value not provided
Outcome 3. GT completion
I:170/170 (100%) C: NR
p value not provided
Outcome 4. Patients identified with
BRCA mutations
I:23/170 (13.5%) C:NR





































Case series with no comparator to
control
Single site tertiary hospital setting
Group 4: Results trend towards the control
(Continued)
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A documentation (referral guidelines and checklist in EMR GC referral) and system (GC
EMR referral) intervention study [46] did not appear to have an impact on completion of GC
(+9.9 (95% CI– 0.41–20.4) p = 0.505), but had a significant effect on GC referral (+12.7 (95%
CI -0.04–25.4) p = 0.053). Regression analysis showed the intervention (p = 0.009), hereditary
risk of cancer (p< 0.0001), and patients living in the metropolitan zone (p = 0.006) affected
GC referral rates between the intervention and control [46] (Table 4). Three of the above stud-
ies [36, 37, 45] were not controlled for confounding variables or regression analysis on the
characteristics inherent in the control verses the intervention population or health system
apart from one [46] and the above interpretation of casual intervention impact needs to be
interpreted with caution.
Complex interventions with interdisciplinary practice. Three studies [34, 38, 55]
included an interdisciplinary practice complex intervention using a genetic counsellor or
oncologist. One study used an interdisciplinary practice (GC embedded into oncology),
Table 4. (Continued)







Genetic Counsellor and Geneticist
Radiation oncologist
Oncology nurses
Oncology and genetics admin
Palliative care
Patients:








process for LS for
healthcare professionals
EMR documentation of
GC/GT and/or referral via
email
MDT documentation of GC
and pathology outcomes
Results tracking
Outcome 1. Eligible for referral to GC
Hospital A +7.24% (95% CI -2.3–17)
Hospital B -1.88% (95% CI -9.4–5.6)
Outcome 2. GC referral
Hospital A -25% (95% CI -71-20)

















Cohort study with historical control
Two hospital sites but with no
analysis on confounding variables or
regression analysis on the
characteristics inherent in the
control verses the intervention













All women with EOC
Healthcare Institution:
A tertiary care centre











Outcome 1. GC referral
+27.4% (95% CI 11.1–43.7, p = 0.02)
Outcome 2. GC completion
-27.8% (95% CI -46.7 to -9.1)
p value not provided
Outcome 3. GT completion
+20.6% (95% CI 5.9–35.4)
p value not provided
Outcome 4. Patients identified with
BRCA mutations

























Cohort study with historical control
Single site health system and no
analysis on confounding variables or
regression analysis on the
characteristics inherent in the
control verses the intervention
population or health system
MDT multidisciplinary team, EMR electronic medical record, EHR electronic health record GC Genetic Counselling, GT Genetic testing, I intervention, C comparator,
NR not recorded, TT tumour testing, UTS universal tumour screening, MSI microsatellite instability testing, IHC immunohistochemistry, TNBC triple negative breast
cancer, BrCa breast cancer, CRC colorectal cancer, VUS variant of unknown significance, EOC epithelial ovarian cancer, LS Lynch syndrome, PARPi poly (ADP-ribose)
polymerase inhibitor
https://doi.org/10.1371/journal.pone.0250379.t004
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documentation (EMR GC and GT referral and completion) and system (GC appointment
scheduling in oncology) complex intervention and led to a significant difference in GC referral
(+22.8 (95% CI 16.7–29.4) p<0.00001) and GC completion rate (+45.5 (95% CI 33.6–57.6)
p<0.00001) between the intervention and control [34]. Similarly, GT completion rate was
impacted using an intervention consisting of education (oncology and breast health profes-
sionals’ education on guidelines), interdisciplinary practice (increase in volume of GC and
telemedicine consults) and documentation (referral to GC was made a standard of practice)
[38]. A significant difference in GT completion was found by cancer or histology type for EOC
(+29% (95% CI 16.8–41.2) p<0.05), TNBC < 60 yrs (+26.6% (95% CI 14.9–38.4) p<0.05) or
breast cancer < 45 yrs (+15.7% (95% CI -7.5–6.1) p<0.05) between the intervention and con-
trol [38] (Table 4). An oncologist led GT intervention [55] with multidisciplinary team (MDT)
communication and case management led to significant increase in GC referral (+25.4% (95%
CI 16.4–34.3) p < 0.0001) and cancer prevention management (+22% (95% CI -16.2–60.3)
p = 0.03), with less of an effect on GT completion between the intervention and control [55].
Similarly, a genetic counsellor at the MDT led to a significant difference in GC referral rates
(+25% (95% CI 13.6–36.4) (P< 0.0001) p< 0.0001), between the intervention and control
[43] (Table 4).
Among the complex interventions described above the common components of education
[45, 36] and use of EMR to document and ensure GC referral occurred [34, 36, 37, 46] appear
to have potential effects on outcomes such as GC referral, completion and GT completion.
Complex interventions with no comparator. For the remaining seven studies, the com-
position of the interventions varied with five studies sharing a common complex intervention
[29, 32, 40, 51, 52] in the UK and two studies from the USA [35, 39] and four studies with inde-
pendent interventions [31, 48, 53, 54]. The complex interventions contained education [29, 32,
40, 35, 39, 51, 52], systems [35, 39], documentation [29, 32, 40, 35, 51–54] and interdisciplinary
practice [35, 48] components (S4 Table). The potential intervention effect in relation to GT
and GC completion rates were unclear with no comparator present to quantify an effect.
Enhancing access to genetic counselling and genetic testing after universal
tumour screening for colorectal and endometrial cancer
Five studies [41, 42, 44, 47, 39] described interventions aimed at enhancing access to GC and
GT after UTS in colorectal and endometrial cancer (S4 Table). The interventions were varied
with education, documentation, interdisciplinary practice or systems related domains
(Table 1). The studies outcomes mapped to Proctor’s evaluative framework [21] at the service
or client level measuring potential effectiveness through GC referral [39, 41, 42, 44, 47] or GC
[39, 41, 44, 47], GT completion rate [39, 41, 44, 47] or identification of hereditary cancer [39,
41, 44] and timely access to GC [44] (Table 2). CFIR [22] process and inner setting implemen-
tation factors were mainly addressed through engaging with health professionals in education
or implementing the intervention [39, 41, 42, 44, 47] and two studies executing the implemen-
tation according to a plan [39, 42].
Two of the five studies showed a potential positive effect in favour of the intervention due
to enhanced GC referral [44], completion of GC and GT [41, 44] and more patients being
identified with hereditary cancer [41, 44] (Table 4).
Complex interventions—Documentation and electronic system. Two studies [47, 41]
used complex interventions, one consisting of education (handouts on LS referral process for
clinicians) and systems (triggered GC referral after abnormal IHC and MSI, shared GC e-mail
to review all abnormal MSI and IHC, electronic communication with physician, scheduling
GC and CRC clinic appointments synchronously and results tracking by nurse) led to an
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absolute difference in GC referral (+9.4 (95% CI -7.9–26.8) and GC (+9.4 (95% CI -7.9–26.8)
or GT completion (+10 (95% CI -47.6–67.6) but with no statistical significant difference
shown [47] (Table 4). Similarly, a systems (triggered GC referral after abnormal IHC and MSI,
pathology communication via e-mail to surgeon) and interdisciplinary practice (patient navi-
gators to ensure follow through to GC for abnormal IHC and MSI) led to an absolute differ-
ence in GC (+45.8% (95% CI 13.6–78.1) p = 0.020) and GT (+12.9%, (95% CI -24.7–50.4)
completion and the identification of hereditary cancer (+28.8% (95% CI -21.5–79.2) between
the intervention and control, with no statistical difference found [41] (Table 4).
Complex interventions with interdisciplinary practice. One study consisting of interdis-
ciplinary practice (GC embedded to review and communication abnormal IHC to patients
and facilitate referral) and systems (triggered EMR GC referral after abnormal IHC and MSI
to surgeon and documentation in EMR) complex intervention led to a significant difference
in, GC referral (+44.7 (95% CI 28.1–60.5) p<0.001) and GC (+39.8% (95% CI 20.9–58.8)
p<0.001) and GT (+39.8% (95% CI 21.1–58.5) p<0.001) completion rates between one arm of
the intervention (genetic counsellor facilitation) and the control [44] (Table 4).
Among the complex interventions described above the common components of triggering
GC referral after abnormal IHC results [41, 44, 47] and use of e-mail communication and
review of IHC results between GC, pathology and surgeon [41, 47] appear to have potential
effects on outcomes such as GC referral, completion and GT completion.
Complex interventions with no comparator. One study [39] had an unclear intervention
effect in relation to GC referral, GT and tumour testing completion rate and identification of
hereditary cancer [39], as no comparator was available for assessment (S4 Table). Of note, all
studies described under this theme had small sample sizes and none were controlled for con-
founding variables or regression analysis on the characteristics inherent in the control verses
the intervention population or health system. As such the above interpretation of casual inter-
vention impact on outcomes measured should be interpreted with caution.
Efficiency and treatment management. Seven studies in breast and ovarian cancer mea-
sured the time taken to access GC or GT [32, 35, 52] and to receive the results of GT [29, 31,
32, 33, 54] after the intervention was implemented (Table 3). Six studies indicated efficiency in
gaining access to GC and results [29, 31–33, 52, 54] and one study noted a reduction in time to
access GC [35] (Table 5). The complex intervention in four studies representing single site
hospitals with either GC services available on site [29, 35] or off site [32, 33] and one multiple
centre study with regional and urban sites had unclear GC access for each site [31]. Three stud-
ies [44, 45, 54] with a historical or concurrent comparator in ovarian [45, 54], and colorectal
[44] cancer showed a potential effect of the intervention in the reduction in time to gain access
to GC and enhancement of familial GT uptake.
System level outcome—Time efficiency. Two studies showed a reduction in time to
receipt of GC [33, 35]. One study with a reduction of time within 42 and 54.5 days to GC and
referral to results access within 106 and 140.5 days in two respective intervention time periods
[33]. The other study reduced time to GC from 197 to 78 days when comparing the interven-
tion and baseline times [35] and a fourfold reduction in time from GC to result was achieved
in another study [29]. The time from sample receipt to result was reduced from 48 to 14 [32],
148.2 to 20.6 [52] days and post-test GC referral between 43 to 12 days [32]. Of note, sites with
GC services available [29, 35] did not appear to show an advantage in time to gain access to
GC in single site centres. However, the above studies did not compare the reduction in time to
a comparator and firm conclusion cannot be drawn from the data presented.
Two studies with a historical or concurrent comparator [44, 54]—in the context of colorec-
tal and ovarian cancer—showed a statistical difference with a reduction in time to gain access
to GC. One study found a time reduction of 413 days (p<0.001) between intervention (when a
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Table 5. Implementation level outcomes of complex interventions in ovarian and subsets of breast cancer.
Study Design Acceptability Cost
George [29] 2016
UK
Case series Satisfaction and comfort with mainstreaming intervention 13-fold reduction in genetics
appointments with annual cost saving of
2.6 million
Quantitative I:105/105 patients were pleased to have had the genetic test






Case series I: 108/300 Nurse NR
Quantitative C: 192/300 Doctor
Survey No difference in patient satisfaction between those consented by a nurse or a
doctorPatients and Health
professionals I: 75/108 patients consented by nurses completed a questionnaire.
No patients refused GT, or requested a GC appointment before GT.
C: NR
Nurses satisfaction with pre-test GC training and role
I: 5/6 nurses found the BRCA training helpful and




Case series I: 173/232 (75%) I: £121 229 mainstreaming pathway
Quantitative low psychological impact to GT compared to cancer diagnosis (p<0.001). C: £130 102 current standard pathway
Survey C: NR Absolute difference = £8,873




Case series A high level of comfort with; the process of consenting and delivering results NR
Quantitative Medical oncologists (n = 6),
Health professionals Less comfort in gynaecology oncologists and trainees (n = 5)
Tutty [48] 2019
UK
Case series I:97.2% and 94.3% were satisfied with the timing of the telephone call and
information provided (n = 107)
I: $91.52 per woman tested (n = 72)
Quantitative C: NR C: $ 107. 37 SIGC (n = 52)
Survey Low score for decisional regret (M = 4.25) Absolute difference cost-saving—$15.85
Patients 72% of the women indicating they had no regret regarding TFGT
The psychological impact of receiving BRCA1/2 results was low
(M = 7.9, SD = 7.5 for a negative test result;
M = 16.8, SD = 9.7 for a positive test result;
M = 12.0, SD = .6.3 for a VUS result)
Kemp [40] 2019
UK
Case series I: 129/259 patients surveyed I: 2,500 genetics appointments
Quantitative 128/128 (100%) -pleased to have GT 124/129 C: 50,000 genetics appointments
Survey 96.1% -happy that GT was via cancer team. 95% reduction in genetic consultation
Patients 23/23 (100%) of cancer team members reported feeling confident to do
BRCA testing during their consultation and believed that the process worked
well
85% reduction in time to test result




Case series I: Decision regret scale M 9.14±12.397–14/29 (48.3%), reported no decision
regret
NR
Quantitative 26/29 (89.6%) were satisfied with their decision to pursue GT. Zero
participants expressed clear dissatisfaction.
Survey All participants felt sufficient time had been given to consider the offer of
mainstreamed genetic testing.
Patients Participants produced low MICRA scores
Distress M = 2.66 ± SD 4.108
Uncertainty M = 5.07± SD 4.154
Positive experiences M = 3.36± SD 4.093
Familial risk M = 7.05± SD 3.027
Ability to cope M = 0.26± SD 0.656 (coping harder with MGT)
M = 2.46± SD 2.134 (coping easier with MGT)
26/29 (89.6%) felt adequately supported by the oncology department.
(Continued)
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Table 5. (Continued)
Study Design Acceptability Cost
Richardson [54]
2020 Canada
Concurrent cohort 259/400 completed survey– 57/259 from the oncology clinic based (OCB)
and 202/259 from the traditional model (TM)
NR
Quantitative Patient Acceptability Scale
Survey OCB M = 4.54, SD = 0.71 vs TM M = 4.52, SD = 0.69
Patients 8/19 oncologists completed survey– 5/8 strongly agreed or agreed with ‘the




OCB M = 4.53, SD = 5.65 vs TM M = 3.37, SD = 5.24
Uncertainty
OCB M = 9.51, SD = 8.19 vs TM M = 10.02, SD = 6.88
Positive experience
OCB M = 6.00, SD = 5.78 vs TM M = 4.45, SD = 4.66
Decisional conflict scale
Uncertainty
OCB M = 22.57, SD = 19.52 vs TM M = 23.36, SD = 21.25
Informed
OCB M = 19.71, SD = 14.04 vs TM M = 18.04, SD = 17.38
Values Clarity
OCB M = 24.13, SD = 17.04 vs TM M = 24.22, SD = 19.73
Support
OCB M = 25.18, SD = 18.23 vs TM M = 26.61, SD = 20.94
Effective Decision
OCB M = 13.16, SD = 14.32 vs TM M = 15.21, SD = 19.43
Genetic Counselling Outcome Scale
OCB M = 120.17, SD = 16.78 vs TM M = 120.93, SD = 15.15
Shipman [50] 2017
UK
Qualitative Motivations and Influences re Offers of GT NR
Interviews Genetic Testing was Just Not Disruptive in the Context of Cancer Diagnosis
17 Patients and
Health Professionals
Illustrative Quote “I mean I was going- I was going through chemo at the
time an, you know, I just wanted to get through the chemo (laughing tone) I
really didn’t really care about you know, as long as I was gonna be all right,
that was all I was concerned about . . .And that’s made a big difference to my
attitude to all the tests and studies and everything” (EOC patient with
mutation identified)
Staff Anxieties
“Once they’ve had a diagnosis they’re bamboozled with the idea of all the
treatment options in front of them or they might be post-surgical and facing
chemo. . .and they’re probably not at the most receptive point to consider




Qualitative Acceptance of TFGT NR
“It’s the same as having an operation. It’s not very pleasant but if you have to
have it, you have to have it” (Invasive ovarian cancer patient eligible for
BRCA testing)
Interviews Perceived advantages of TFGT
“But I just think that more information, yes it’s scary, but the more you know
the better off you are to be able to make a decision” (Invasive ovarian cancer
patient eligible for BRCA testing)
22 Patients Perceived need to make TFGT a routine test
“I believe that it should be incorporated into the overall testing because then
it ultimately gives the treating oncologist like a much bigger picture and the
full picture” (Invasive ovarian cancer patient eligible for BRCA testing)
GC Genetic Counselling, GT Genetic testing, I intervention, C comparator, NR not recorded, TFGT treatment focused genetic testing, OCB oncology clinic based, TM
traditional model, MICRA Multidimensional Impact of Cancer Risk Assessment
https://doi.org/10.1371/journal.pone.0250379.t005
PLOS ONE Interventions to integrate genetic testing into routine oncology services
PLOS ONE | https://doi.org/10.1371/journal.pone.0250379 May 19, 2021 27 / 36
GC was involved in receiving IHC results along with the surgeon and facilitated results com-
munication between patient and making a GC referral) and control (no GC involved and all
IHC results sent to surgeon and GC referral made at surgeon discretion) [44]. The other study
showed a time reduction to gain access to GT results of 212 days (p<0.001) between the inter-
vention (direct access to pre-test GC and panel GT through oncologists in an oncology clinic-
based model with post-test GC provided by a genetic counsellor) versus the control (referral to
GC) [54] (Table 4 and S4 Table).
Client level outcome—Treatment management. Four studies described the treatment
impact of direct access to GT in routine oncology care for EOC [29, 33, 52, 55] (Table 4 and S4
Table). Treatment was informed in 132/207 of ovarian cancer patients either at first line ther-
apy or relapse of their disease with 20/23 women [29] and 6/18 women with BRCA mutations
gaining access to PARPi [32]. Ovarian cancer patients with BRCA pathogenic variants (32/33)
had breast cancer surveillance [29] and breast cancer patients had significantly more risk
reducing measures compared with the control (+22% (95% CI -16.2–60.3) p = 0.03) [55] with
the oncologist led intervention (oncologist led pathway, communication and MDT) compared
to control (usual care and referral pathway to a genetics unit). PARPi was received by 9/34
BRCA pathogenic variant women with ovarian cancer, with 5/34 indicated to initiate PARPi,
in the future [52] (Table 4 and S4 Table).
Three studies described the family management of BRCA through the uptake of predictive
GT in family members [32, 33, 45]. At risk family members accessed predictive GT with vary-
ing degrees from 31/120 [33] to 11/ 15 [32] in the study time period. Predictive GT and identi-
fication of BRCA carriers significantly increased per histology subtype in the intervention
(education on benefit of GC referral for cancer prevention and inclusion on pathology report-
ing) arm from 2.54 to 3.27 (p = 0.071) and 1.62 and 2.18 (p = 0.009) compared to the control
(usual care with no education or pathology reporting GC recommendations), respectively [45]
in ovarian cancer families (Table 4 and S4 Table).
Implementation level outcome and factors. Eight studies assessed the acceptability of
the intervention used to introduce routine GT into oncology care of EOC [29–31, 33, 48, 51,
54] and for subsets of breast cancer patients [40, 54] (Tables 3 and 5). Four studies assessed sat-
isfaction of the new process from the patients and healthcare professional perspective using
survey style questions [29, 30, 40, 54] and mapped to CFIR outer setting of patient needs and
resources. Implementation factors addressed through CFIR showed that only a minority of
studies focused on reflecting and evaluation the implementation efforts through health profes-
sionals’ feedback about the intervention [40, 42, 54], their belief with regards to their ability to
undertake the intervention [29, 30, 33, 40] and the cost or cost savings with such efforts [29,
31, 40, 48] (Tables 3 and 5).
Implementation level outcome—Acceptability. Two studies [29, 40] showed most
patients were pleased to have had the genetic test and via the cancer team [40] and all health-
care professionals involved were comfortable with consenting for GT [29] and felt confident to
provide BRCA testing, believing the process worked well [40]. Patient satisfaction between GT
consented by a nurse or a doctor was not impacted amongst surveyed participants [30], with
no patients refusing GT or requesting a GC appointment beforehand with nurses consenting
[30]. The majority of nurses found the BRCA training helpful, saw BRCA testing as part of
their role and felt supported [30]. Five studies assessed satisfaction either from the patient [31,
48, 51, 54] or the healthcare professional perspective [33, 54]. The majority of patients were
satisfied with the timing of the telephone call, their decision to pursue GT [51] and the infor-
mation provided, indicating they had sufficient information and time to decide to have GT
[48, 51]. Overall, women indicated high scores of satisfaction based on the Genetic Counselling
Satisfaction Scale (GCSS [58]) [48, 54]. Healthcare professionals indicated a high level of
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comfort with the process of consenting to and delivering results for GT amongst the medical
oncologists [33, 54], but less so amongst the gynaecology oncologists and trainees [33]. All
except two [48, 54] of the above studies used self-designed survey question with no validated
measures of satisfaction to evaluate this aspect of acceptability. The reliability and validity of
the results are limited in this regard.
Four studies evaluated the psychological impact of receiving GT during the cancer diagno-
sis and treatment period [31, 48, 51, 54]. Low patient scores on psychological impact to GT
compared to their cancer diagnosis were found with validated measures such as the impact of
events scale (IES) [59] and Depression, anxiety and stress scale (DASS -21 [60]) [31]. The only
difference in population characteristics was younger age and mutation status, leading to more
intrusive thoughts (IES intrusion r = −0.172, p = 0.026) and significantly more stress (DASS
stress r = 0.162, p = 0.014) and cognitive avoidance scores based on BRCA pathogenic variant
status, respectively [33]. Patients indicated a low score for decisional regret and psychological
impact [48, 51, 54] of GT results, in relation to their decision to undergo treatment-focused
genetic testing (TFGT) and receiving results [48]. Validated measures such as the decisional
regret scale [61] and the multidimensional impact of risk assessment [62] were used respec-
tively. Validated measures strengthen the results reporting acceptability of the new approach
from the patients’ perspective and can be reliably reproduced in future studies on acceptability
of interventions.
Two qualitative studies support the acceptability of routine GT in oncology for ovarian can-
cer patients [49, 50] (Table 5). Both the 12 ovarian patients who had TFGT and those who
were asked hypothetically found the concept of TFGT to be acceptable and wanted it as a rou-
tine test to inform their care [49]. Seventeen patients and five staff members offered or
involved in TFGT [31] did not see GT as disruptive in the overall experience of having a cancer
diagnosis [50]. However, some staff expressed concern about overburdening recently diag-
nosed patients undergoing chemotherapy. Both qualitative studies support the implementa-
tion outcome of acceptability of incorporating GT into routine oncology.
Implementation level outcome—Cost. Four studies assessed the cost and resources
needed to implement routine GT [29, 31, 40, 48] into oncology when mapped to both Proctor’s
evaluative lens and CFIR intervention characteristics of cost (Tables 3 and 5). Two studies [29,
40] evaluated the reduction in genetics appointments and cost. A 13-fold reduction in genetics
appointments, with an annual cost saving of 2.6 million for the mainstreaming pathway in
ovarian cancer was found in one study [29]. Another study found a 95% reduction in genetic
consultation, with an 85% reduction in time to test result for the mainstreaming pathway for
subsets of breast cancer [40]. The cost of the pathway or testing per patient in the mainstream-
ing versus the traditional pathway showed a cost reduction of UK£8,873 [31] for the former
and AUS $15.85 [48] for the later. A robust economic analysis was not evident in the above
studies and many lacked a comparator to strengthen the evidence regarding cost reduction.
Discussion
This systematic review aimed to examine health system interventions used to increase the
uptake of GC and GT in oncology services to identify hereditary breast, ovarian, colorectal and
endometrial cancer. The evidence indicates that complex interventions have a potentially posi-
tive effect on GC and GT completion rates in oncology services. Twenty-five studies identified
intervention characteristics, with eight of these also describing implementation factors that
influenced access to GT, GC and identification of hereditary cancer. The health professional
groups targeted by the interventions were varied. About one-quarter of studies included an
implementation science model or framework to guide intervention design or implementation
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and high priority CFIR constructs were not always applied in studies to understand the imple-
mentation factors.
Many types of health professionals were targeted with the designed intervention mainly
focusing on oncologists or surgeons, advanced practice nurses or clinical nurse specialists,
pathologists or genetic counsellors. A broader range of healthcare professionals such as radiog-
raphers, gastroenterologists and colorectal surgeons could be included in future GT integra-
tion programs in oncology through breast or CRC screening programs, once these health
professionals have been appropriately skilled [63–65].
As described above, about one quarter of the studies included an implementation science
framework or a quality improvement model to guide intervention design and implementation.
However, the interaction between the intervention and the theory behind the strategies was
not addressed from the above studies and thus limits generalizable lessons. Evidence based
pre-implementation research underpinned with implementation theory is crucial in guiding
the development and evaluation of interventions [66]. In future, more studies using a theory-
based evaluation of implementation-level outcomes are needed to better understand interven-
tion implementation efforts. Some high priority CFIR constructs identified by the Implement-
ing GeNomics In PracTicE (IGNITE) [67] model were present in the included studies apart
from intervention characteristics (relative advantage), individuals characteristics (knowledge
and belief about the intervention) and inner setting (implementation climate). Future geno-
mics implementation research incorporating all high priority constructs would aid in a
broader understanding of genomics implementation factors in diverse contexts and systems.
Strengths and limitations
Our review provides a comprehensive and rigorous assessment of interventions to integrate
GT in oncology. It is the first to assess GT mainstreaming programs and apply a recognised
implementation science outcome [21] and determinant framework [22] to identify common
client, service or implementation outcomes in assessing intervention effectiveness and imple-
mentation factors. The data aligned with some of the high priority CFIR constructs identified
as important to assess in genomics implementation research. Most studies used complex inter-
ventions that can inform implementation strategies for future genomics implementation
research.
Regarding limitations, the inclusion of a variety of study designs and intervention types pre-
cluded the conduct of a meta-analysis. With this variation, no specific quality measure was
available to evaluate the diverse literature. The adaptation of the NOS addressed the potential
bias in studies by developing specific implementation intervention assessment criteria (S5 and
S6 Tables). Many studies had poor methodological design and reported on few outcomes
across the implementation level. A lack of focus on implementation outcomes impacts the
understanding of what will contribute to the longer-term sustainability of GT integration in
health systems.
Across the included studies, there was a lack of consistency in classification of interventions
and the strategies used to implement them. A classification system (Table 1) was created to
apply parameters to intervention characteristics and provide a means to analyse a potential
effect. However, the mechanisms and data that explain why an intervention may, or may not,
yield change were unclear. Those studies that did use a framework or theory rarely addressed
the interaction between these and the strategies selected. This limits the generalizable lessons
that might have been learned from these studies. Finally, the calculated absolute difference
value cannot conclusively provide accurate estimates about the impact of a particular
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component of an intervention due to the heterogeneity of intervention characteristics, variabil-
ity of health systems and range of health professionals involved.
The majority of studies were single site, urban hospital settings, which limits generalisabil-
ity. However, a wide variety of health systems structures implementing complex interventions
were represented in the included studies, allowing understanding of the possible implementa-
tion strategies that may work in similar settings.
Implications for research and policy
Our findings indicate that complex interventions–using systems, education, documentation
and interdisciplinary practice–have a potential positive effect on GC and GT outcomes in vari-
ous cancer types. The majority of the studies were of small sample size and did not collect lon-
gitudinal data or utilize an evaluation framework to underpin the intervention effectiveness
findings with an assessment of all outcomes at the client, service and implementation level.
Future research requires more rigorous study and evaluation designs by examining the patient,
provider, organization and policy levels of healthcare to improve health outcomes [66].
The optimisation of patient outcomes requires implementation research to align with the
real-world problems and priorities of healthcare organisations [2]. As more GT is main-
streamed into routine oncology care, future interventions need to fit with organizational work-
flows and processes to encourage successful implementation. Hybrid study designs allow for
simultaneous measurement of intervention and implementation effectiveness [68]. Similarly,
step wedge designs allow interventions to be introduced and evaluated in a staged way and to
compare the effects of implementation [69] across different hospital settings [70].
Furthermore, pre-implementation research that identifies organisation characteristics and
barriers and then tailor interventions to address these adds value to the likely adoption of new
innovations [71]. In our review, a minority of studies assessed acceptability as part of the inter-
vention implementation efforts; evidence from other qualitative studies supports the accept-
ability and feasibility of integrating GT into oncology services [72]. Future research with a pre-
implementation focus on implementation outcomes and defined intervention characteristics
could enhance understanding of the factors that influence GT integration implementation
efforts.
Conclusion
This systematic review contributes new knowledge to the genomics implementation field by
summarizing and assessing the characteristics and outcome findings of mainstreaming GT
programs and uptake of GT after UTS. The existing evidence on intervention effectiveness
suggests GT mainstreaming programs increase access to GC and GT in oncology services.
However, there is a significant gap in understanding the interaction between the intervention
and implementation theory to harness generalizable implementation strategies. Future pri-
mary research studies with robust methodological quality informed by theory are required.
Results from this systematic review could inform future implementation strategies to integrate
genetics into routine care of oncology health systems.
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55. Lobo M, López-Tarruella S, Luque S, Lizarraga S, Flores-Sánchez C, Bueno O, et al. Evaluation of
Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation
of a Heredofamilial Cancer Unit. J Genet Couns. 2018; 27:854–862. https://doi.org/10.1007/s10897-
017-0187-3 PMID: 29247312
56. Institute of Medicine (US) Committee on Crossing the Quality Chasm. Adaption to mental health and
addictive disorder: Improving the quality of health care for mental and substance use conditions. Wash-
ington, DC: Institute of Medicine, National Academies Press; 2006.
57. Institute of Medicine (US) Committee on Quality of Health Care in America. Crossing the quality chasm:
A new health system for the 21st century. Washington, DC: Institute of Medicine, National Academy
Press;2001.
58. DeMarco TA, Peshkin BN, Mars BD, Tercyak KP. Patient satisfaction with cancer genetic counseling: a
psychometric analysis of the genetic counseling satisfaction scale. J Genet Couns.2004; 13:293–304
https://doi.org/10.1023/b:jogc.0000035523.96133.bc PMID: 19736695
59. Horowitz MJ, Hulley S, Alvarez W, Reynolds AM, Benfari R, Blair S, et al. Life events, risk factors, and
coronary disease. Psychosomatics. 1979; 20:586–92. https://doi.org/10.1016/S0033-3182(79)70763-8
PMID: 493483
60. Lovibond PF, Lovibond SH. The structure of negative emotional states: comparison of the Depression
Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther
1995; 33:335–43. https://doi.org/10.1016/0005-7967(94)00075-u PMID: 7726811
PLOS ONE Interventions to integrate genetic testing into routine oncology services
PLOS ONE | https://doi.org/10.1371/journal.pone.0250379 May 19, 2021 35 / 36
61. Brehaut J, O’Connor A, Wood T, Hack T, Siminoff L, Gordon E, et al. Validation of a decision regret
scale. Med Decis Making. 2003; 23:281–92. https://doi.org/10.1177/0272989X03256005 PMID:
12926578
62. Cella D, Hughes C, Peterman A, Chang C-H, Peshkin BN, Schwartz MD, et al. A brief assessment of
concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk
Assessment (MICRA) questionnaire. Health Psychol. 2002; 21:564. PMID: 12433008
63. Manchanda R, Patel S, Gordeev VS, Antoniou AC, Smith S, Lee A, et al. Cost-effectiveness of Popula-
tion-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected Gen-
eral Population Women. J Natl Cancer Inst. 2018; 110:714–725. https://doi.org/10.1093/jnci/djx265
PMID: 29361001
64. Manchanda R, Legood R. Population based germline testing for primary cancer prevention. Oncotarget.
2018; 9: 33062–33063. https://doi.org/10.18632/oncotarget.25995 PMID: 30237851
65. Veldwijk J, Lambooij MS, Kallenberg FGJ, van Kranen HJ, Bredenoord AL, Dekker E, et al. Preferences
for genetic testing for colorectal cancer within a population-based screening program: a discrete choice
experiment. Eur J Hum Genet. 2016; 24: 361–366. https://doi.org/10.1038/ejhg.2015.117 PMID:
26036860
66. Brown CH, Curran G, Palinkas LA, Aarons GA, Wells KB, Jones L, et al. An Overview of Research and
Evaluation Designs for Dissemination and Implementation. Annu Rev Public Health. 2017; 38:1–22
https://doi.org/10.1146/annurev-publhealth-031816-044215 PMID: 28384085
67. Orlando LA, Sperber NR, Voils C, Nichols M, Myers RA, Wu R, et al on behalf of the IGNITE Network.
Developing a Common Framework for Evaluating the Implementation of Genomic Medicine Interven-
tions in Clinical Care: The IGNITE Network’s Common Measures Working Group. Genet Med. 2018;
20:655–663. https://doi.org/10.1038/gim.2017.144 PMID: 28914267
68. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs:
combining elements of clinical effectiveness and implementation research to enhance public health
impact. Med Care 2012; 50:217–26. https://doi.org/10.1097/MLR.0b013e3182408812 PMID:
22310560
69. Hussey MA, Hughes JP. Design and analysis of stepped wedge cluster randomized trials. Contemp
Clin Trials. 2007; 28:182–91. https://doi.org/10.1016/j.cct.2006.05.007 PMID: 16829207
70. Kallenberg FGJ, Aalfs CM, The FO, Wientjes CA, Depla AC,�Mundt MW, et al. Evaluation of an online
family history tool for identifying hereditary and familial colorectal cancer. Fam Cancer. 2018; 17:371–
380. https://doi.org/10.1007/s10689-017-0041-7 PMID: 28936633
71. Damschroder LJ, Hagedorn HJ. A guiding framework and approach for implementation research in sub-
stance use disorders treatment Psychology of addictive behaviors. J Soc Psychol Addic Behav. 2011;
25:194–205.
72. Scheinberg T, Young A, Woo H, Goodwin A, Mahon KL, Horvath LG. Mainstream consent programs for
genetic counseling in cancer patients: A systematic review. Asia-Pac J Clin Oncol. 2020;1–15. https://
doi.org/10.1111/ajco.13334 PMID: 32309911
PLOS ONE Interventions to integrate genetic testing into routine oncology services
PLOS ONE | https://doi.org/10.1371/journal.pone.0250379 May 19, 2021 36 / 36
